Arcturus Therapeutics ARCT Stock
Arcturus Therapeutics Price Chart
Arcturus Therapeutics ARCT Financial and Trading Overview
| Arcturus Therapeutics stock price | 30.43 USD |
| Previous Close | 27.63 USD |
| Open | 27.73 USD |
| Bid | 0 USD x 1000 |
| Ask | 0 USD x 1800 |
| Day's Range | 27.26 - 28.07 USD |
| 52 Week Range | 12.53 - 33.8 USD |
| Volume | 230.72K USD |
| Avg. Volume | 516.2K USD |
| Market Cap | 729.95M USD |
| Beta (5Y Monthly) | 2.604929 |
| PE Ratio (TTM) | 6.9045224 |
| EPS (TTM) | -1.12 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 51.79 USD |
ARCT Valuation Measures
| Enterprise Value | 435.19M USD |
| Trailing P/E | 6.9045224 |
| Forward P/E | -7.873925 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2.5973215 |
| Price/Book (mrq) | 2.2163076 |
| Enterprise Value/Revenue | 1.548 |
| Enterprise Value/EBITDA | 5.495 |
Trading Information
Arcturus Therapeutics Stock Price History
| Beta (5Y Monthly) | 2.604929 |
| 52-Week Change | 104.00% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 33.8 USD |
| 52 Week Low | 12.53 USD |
| 50-Day Moving Average | 27.57 USD |
| 200-Day Moving Average | 19.91 USD |
ARCT Share Statistics
| Avg. Volume (3 month) | 516.2K USD |
| Avg. Daily Volume (10-Days) | 278.09K USD |
| Shares Outstanding | 26.56M |
| Float | 22.93M |
| Short Ratio | 8.09 |
| % Held by Insiders | 13.82% |
| % Held by Institutions | 81.49% |
| Shares Short | 3.61M |
| Short % of Float | 18.19% |
| Short % of Shares Outstanding | 13.60% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:7 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 39.59% |
| Operating Margin (ttm) | 27.50% |
| Gross Margin | 46.65% |
| EBITDA Margin | 28.17% |
Management Effectiveness
| Return on Assets (ttm) | 11.88% |
| Return on Equity (ttm) | 43.29% |
Income Statement
| Revenue (ttm) | 281.04M USD |
| Revenue Per Share (ttm) | 10.61 USD |
| Quarterly Revenue Growth (yoy) | 1431.00% |
| Gross Profit (ttm) | 62.95M USD |
| EBITDA | 79.19M USD |
| Net Income Avi to Common (ttm) | 111.27M USD |
| Diluted EPS (ttm) | 3.98 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 327.94M USD |
| Total Cash Per Share (mrq) | 12.35 USD |
| Total Debt (mrq) | 33.17M USD |
| Total Debt/Equity (mrq) | 10.08 USD |
| Current Ratio (mrq) | 4.71 |
| Book Value Per Share (mrq) | 12.399 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 45.16M USD |
| Levered Free Cash Flow (ttm) | -11117875 USD |
Profile of Arcturus Therapeutics
| Country | United States |
| State | CA |
| City | San Diego |
| Address | 10628 Science Center Drive |
| ZIP | 92121 |
| Phone | 858 900 2660 |
| Website | https://arcturusrx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 170 |
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.
Q&A For Arcturus Therapeutics Stock
What is a current ARCT stock price?
Arcturus Therapeutics ARCT stock price today per share is 30.43 USD.
How to purchase Arcturus Therapeutics stock?
You can buy ARCT shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Arcturus Therapeutics?
The stock symbol or ticker of Arcturus Therapeutics is ARCT.
Which industry does the Arcturus Therapeutics company belong to?
The Arcturus Therapeutics industry is Biotechnology.
How many shares does Arcturus Therapeutics have in circulation?
The max supply of Arcturus Therapeutics shares is 26.92M.
What is Arcturus Therapeutics Price to Earnings Ratio (PE Ratio)?
Arcturus Therapeutics PE Ratio is now.
What was Arcturus Therapeutics earnings per share over the trailing 12 months (TTM)?
Arcturus Therapeutics EPS is -1.12 USD over the trailing 12 months.
Which sector does the Arcturus Therapeutics company belong to?
The Arcturus Therapeutics sector is Healthcare.
Arcturus Therapeutics ARCT included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}